HEMATOLOGIC MALIGNANCIES

This study aims to find the safest, most effective dose of an immune-suppressing drug (cyclophosphamide) for patients aged 65 and older who receive a stem cell transplant for blood cancers. Researchers want to see if a lower dose can still prevent complications from the transplan…

This study is tracking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in patients who were already receiving it in previous Merck trials. It will follow 3,500 people with various solid tumors or blood cancers to see how they do over an extended…

This study is testing a new combination of drugs designed to prevent a dangerous complication called graft-versus-host disease (GVHD) after a bone marrow transplant. The goal is to see if this approach is safe and effective for people living with HIV who have blood cancers that c…

This study allows patients with blood cancers who are benefiting from tafasitamab treatment in previous trials to continue receiving the medication. The main goal is to monitor safety while providing ongoing treatment to those who need it. Only patients already responding well to…

This is the first human study of an experimental drug called INCA036873 for people with advanced cancers that have stopped responding to standard treatments. The main goal is to find the safest dose and understand how the drug moves through the body. The study will enroll 280 adu…

This study is testing a new approach for adults with aggressive blood cancers that are hard to cure. It combines two powerful treatments—a bone marrow transplant from a partially matched donor and genetically modified immune cells (CAR-T cells)—given at the same time. The goal is…

This study is testing whether a different medication approach can better prevent chronic graft-versus-host disease (GVHD) after stem cell transplants for blood cancers. Researchers will compare a new strategy using the drug ruxolitinib against the standard prevention method. The …

This is the first time a new drug called RJK-RT2831 is being tested in people. The main goal is to find a safe dose and check for side effects in about 70 adults with advanced blood cancers like leukemia that have come back or haven't responded to standard treatments. Researchers…

This early-stage study is testing the safety and best dose of a special immune cell infusion given after a stem cell transplant. The goal is to help the new immune system fight cancer while reducing a dangerous side effect called graft-versus-host disease. The study will enroll 3…

This program provides expanded access to a special two-part stem cell transplant for patients with high-risk blood cancers or genetic disorders who cannot find a perfectly matched donor. It uses stem cells from a partially matched family member to provide a temporary 'bridge' whi…

This is the first study in people to test a new cancer drug called IM-1021. The main goals are to find a safe dose and see how the body processes the drug in adults with advanced solid tumors or blood cancers that have not responded to standard treatments. Researchers will also l…

This study is testing a personalized approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Doctors will adjust the strength of the chemotherapy and radiation given before the transplant based on each patient's specific health and disease risk…

This study is testing whether giving patients antibody replacement therapy (IVIG) can prevent serious bacterial infections after they receive a powerful cancer treatment called CD19 CAR-T cell therapy. CAR-T therapy can leave patients with low antibody levels, making them vulnera…

This study provides access to cord blood units that are not yet FDA-approved for patients who need a transplant for blood cancers or other serious blood/immune disorders. It aims to see how well patients' immune systems recover after receiving these transplants and to monitor for…

This study is testing a new drug called SLS009 for people with advanced blood cancers that have come back or stopped responding to treatment, and for newly diagnosed patients with high-risk forms of leukemia. The main goals are to find a safe dose and see if the drug, given alone…

This study is testing an oral drug called nemtabrutinib in people with several types of advanced blood cancers that have come back or stopped responding to other treatments. It aims to find a safe and effective dose and see how well the drug shrinks tumors and controls the diseas…

This study is testing a second stem cell transplant using donated umbilical cord blood for patients whose high-risk blood cancer has returned after their first transplant. The goal is to see if using a less intense pre-transplant treatment can help control the disease and improve…

This study is testing an experimental inhaled drug, PUL-042, to see if it can reduce the severity of lung infections caused by common respiratory viruses in a very vulnerable group. The participants are adults with blood cancers or who have received a stem cell transplant, and wh…

This study is testing whether combining two drugs, ICP-248 and orelabrutinib, is safe and effective for people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who haven't received treatment yet. Researchers will enroll about 226 adults to see how w…

This study is testing a digital health program designed to help patients and their family caregivers during and after outpatient CAR-T cell therapy, a treatment for blood cancers. The program uses remote monitoring to track patient symptoms and caregiver stress, aiming to improve…

This early-stage study aims to understand how the cancer drug pralatrexate is processed by the body in people with varying degrees of liver impairment. It will involve about 24 adults with advanced solid tumors or blood cancers. The main goal is to measure drug levels in the bloo…

This study is testing a new tool called PRIME that helps older adults with blood cancers and their doctors discuss treatment priorities. It compares whether using this tool helps patients feel their final treatment decision better matches their personal values compared to standar…

This study aims to understand how certain leukemia and lymphoma drugs, called BTK inhibitors, affect the heart and may increase the risk of dangerous irregular heartbeats. Researchers will monitor 135 adults who are already taking or planning to start these drugs, using heart tes…

This study aims to create the first detailed, long-term record of lymphoma patients in Malawi. Researchers will enroll 800 people with suspected lymphoma, perform standard biopsies for accurate diagnosis, and follow their health for up to five years. The goal is to gather reliabl…